You are here: Industry Insights > Novartis

News List

EC approves Novartis’s Kesimpta for relapsing multiple sclerosis pharmaceutical-technology
April 01, 2021
The European Commission has approved Novartis’s Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.
Novartis signs deal with iTheranostics to develop, commercialise compounds targeting FAP expresspharma
March 31, 2021
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialise therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74.
Novartis UK signs digital partnership with Cievert for chronic disease management pharmatimes
March 30, 2021
Novartis UK and digital health company Cievert have announced a digital innovation partnership to help streamline the management of rheumatological and dermatological diseases.
Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy prnasia
March 11, 2021
Novartis announced that the Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue and gene therapy products (CTGTP) ...
Novartis’ canakinumab fails to meet primary endpoint in lung cancer trial pharmaceutical-technology
March 10, 2021
Novartis has reported that the Phase III CANOPY-2 study of canakinumab (ACZ885) in combination with the chemotherapy agent docetaxel failed to meet the primary endpoint of overall survival (OS) in patients with advanced or metastatic non-small cell ...
CureVac, Novartis Ink COVID Vax Mfg. Pact contractpharma
March 05, 2021
Novartis to manufacture the mRNA and bulk drug product of the CVnCoV vaccine for up to 50 million doses by the end of 2021.
NICE recommends routine funding for Novartis’ Kisqali pharmatimes
March 01, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients.
UK to revolutionise oligonucleotide medicines manufacturing europeanpharmaceuticalreview
February 25, 2021
Collaborators on Grand Challenge 3 will utilise their combined expertise to transform the oligonucleotide supply chain.
Novartis, Gates Foundation to Develop Accessible Gene Therapy for Sickle Cell Disease americanpharmaceuticalreview
February 20, 2021
Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure SCD.
Entresto Granted Expanded Indication in Chronic Heart Failure by FDA americanpharmaceuticalreview
February 19, 2021
Novartis announced the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page